Avalyn Pharma Statistics
Total Valuation
Avalyn Pharma has a market cap or net worth of $1.20 billion. The enterprise value is $1.06 billion.
| Market Cap | 1.20B |
| Enterprise Value | 1.06B |
Important Dates
The last earnings date was Wednesday, June 3, 2026, before market open.
| Earnings Date | Jun 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Avalyn Pharma has 41.81 million shares outstanding.
| Current Share Class | 41.81M |
| Shares Outstanding | 41.81M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 16.45% |
| Float | 25.59M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 8.98 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.19, with a Debt / Equity ratio of 0.01.
| Current Ratio | 10.19 |
| Quick Ratio | 9.86 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -68.34% and return on invested capital (ROIC) is -45.46%.
| Return on Equity (ROE) | -68.34% |
| Return on Assets (ROA) | -41.74% |
| Return on Invested Capital (ROIC) | -45.46% |
| Return on Capital Employed (ROCE) | -67.73% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.70M |
| Employee Count | 50 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 52.14 |
| Average Volume (20 Days) | 257,664 |
Short Selling Information
The latest short interest is 562,374, so 1.35% of the outstanding shares have been sold short.
| Short Interest | 562,374 |
| Short Previous Month | n/a |
| Short % of Shares Out | 1.35% |
| Short % of Float | 2.20% |
| Short Ratio (days to cover) | 0.60 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -91.29M |
| Pretax Income | -85.20M |
| Net Income | -85.20M |
| EBITDA | -91.25M |
| EBIT | -91.29M |
| Earnings Per Share (EPS) | -$4.56 |
Balance Sheet
The company has $138.41 million in cash and $1.67 million in debt, with a net cash position of $136.74 million or $3.27 per share.
| Cash & Cash Equivalents | 138.41M |
| Total Debt | 1.67M |
| Net Cash | 136.74M |
| Net Cash Per Share | $3.27 |
| Equity (Book Value) | 133.57M |
| Book Value Per Share | -10.11 |
| Working Capital | 129.47M |
Cash Flow
In the last 12 months, operating cash flow was -$81.48 million and capital expenditures -$344,000, giving a free cash flow of -$81.83 million.
| Operating Cash Flow | -81.48M |
| Capital Expenditures | -344,000 |
| Depreciation & Amortization | 42,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -81.83M |
| FCF Per Share | -$1.96 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Avalyn Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -7.11% |
| FCF Yield | -6.83% |
Analyst Forecast
The average price target for Avalyn Pharma is $59.00, which is 105.79% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $59.00 |
| Price Target Difference | 105.79% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |